Vasdev Lohano, MD
Endocrinology, Diabetes & Metabolism · Washington, INNPI 1316906738
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,298 of the $6,075 with a category attached, or 70.7%. 29 manufacturers reported payments, led by Novo Nordisk at 32.7% of the total. Reporting peaked in 2023 at $2,388 and has fallen 78.0% since, to $524 in 2025.
Across 123 payments — averaging $49.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Insulet Corporation$426
- Sanofi-aventis U.S. LLC$336
- Dexcom, Inc.$268
- AstraZeneca$267
- Medtronic$257
- plus $3K from 23 others
Across 12 payments — averaging $384.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$5K
What the payments were for
- Consulting fees$1,74029%
- Food & beverage$4,29871%
- Education$381%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 10 | $1,984 |
| Insulet Corporation | 13 | $426 |
| Sanofi-aventis U.S. LLC | 8 | $336 |
| Dexcom, Inc. | 11 | $268 |
| AstraZeneca(2 entities) | 7 | $267 |
| Medtronic(2 entities) | 6 | $257 |
| Amgen | 8 | $220 |
| Abbott | 6 | $213 |
| Boehringer Ingelheim | 14 | $175 |
| Shire North American Group Inc | 5 | $159 |
| Corcept Therapeutics | 3 | $149 |
| Lilly USA, LLC | 3 | $147 |
| Abiomed | 1 | $146 |
| Amryt Pharma Holdings Ltd | 1 | $139 |
| Neurocrine Biosciences, Inc. | 1 | $131 |
| Bayer | 1 | $125 |
| Sanofi | 1 | $125 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| BETA Bionics, Inc. | 1 | $114 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $113 |
| Radius Health, Inc. | 1 | $105 |
| Amarin Pharma, Inc. | 5 | $90 |
| Merck | 5 | $76 |
| Johnson & Johnson | 5 | $67 |
| Mannkind Corporation | 1 | $46 |
| AbbVie | 1 | $24 |
| Averitas Pharma Inc. | 1 | $19 |
| Tandem Diabetes Care, Inc. | 1 | $16 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$342
- Omnipod$227
- MYCAPSSA$139
- CRENESSITY$131
- TZIELD$126
- Kerendia$125
- FARXIGA$125
- FABRAZYME$125
- NEXLIZET$125
- NEXLETOL$125
- FreeStyle Libre$124
- Korlym$122
- DEXCOM G7 GSS (161)$119
- MOUNJARO$114
- PRALUENT$111
- EVENITY$110
- MINIMED 780G$106
- Tymlos$105
How this compares
$6,075 in reported general payments places this provider in the 70th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 970 | $1,289,526 |
| MounjaroTirzepatide | 897 | $1,212,626 |
| JardianceEmpagliflozin | 1,178 | $1,083,930 |
| Tresiba Flextouch U-100Insulin Degludec | 444 | $303,653 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 293 | $271,042 |
| TrulicityDulaglutide | 185 | $237,963 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 227 | $207,886 |
| FarxigaDapagliflozin Propanediol | 161 | $168,704 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 84 | $124,304 |
| Humalog Kwikpen U-100Insulin Lispro | 436 | $123,498 |
| Tresiba Flextouch U-200Insulin Degludec | 92 | $114,962 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 709 | $109,214 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 264 | $80,318 |
| Novolog FlexpenInsulin Aspart | 277 | $68,294 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 138 | $59,657 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $147 | $1,491,8821,232 claims |
| Novo NordiskOzempic, Novolog, Fiasp | $1,984 | $1,325,2871,070 claims |
| Boehringer IngelheimJardiance, Tradjenta | $175 | $1,102,6571,206 claims |
| MerckJanumet Xr, Janumet, Januvia | $76 | $297,237317 claims |
| AstraZenecaFarxiga | $267 | $168,704161 claims |
| AbbVieSynthroid | $24 | $17,445285 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Washington
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Emily VeenemanSeymour$583K
- Nihad MuhrezMerrillville$271K
- Hisham AllababidiIndianapolis$195K
- Neha GavinFishers$149K
- Edward RicoTerre Haute$135K
- Dona GrayLafayette$92K
- Michael EconsIndianapolis$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.